Adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapy
- 1 June 2013
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in AIDS
- Vol. 27 (9), 1403-1412
- https://doi.org/10.1097/qad.0b013e32835f1db0
Abstract
Introduction: Since 2002, the WHO has recommended either nevirapine (NVP) or efavirenz (EFV) as part of first-line antiretroviral therapy. These two drugs are known to have differing toxicity profiles, but the risk of these toxicities overall is not well established. Methods: We systematically reviewed adverse events among treatment-naive HIV-positive adults and children receiving either NVP or EFV as part of first-line antiretroviral therapy. The primary outcome was drug discontinuation as a result of any adverse event; specific toxicities were evaluated as secondary outcomes. Point estimates and 95% confidence intervals (95% CIs) were calculated and proportions and odds ratios (ORs) pooled using fixed-effects meta-analysis. Results: We reviewed data on 26 446 adults and 3975 children from eight randomized trials and 26 prospective cohorts. Overall, adults on NVP were more than two times more likely to discontinue treatment due to any adverse event compared to patients on EFV (OR 2.2, 95% CI 1.9-2.6). Severe hepatotoxicity (OR 3.3, 95% CI 2.5-4.2), severe skin toxicity (OR 3.9, 95% CI 2.5-5.4), and severe hypersensitivity reactions (OR 2.4, 95% CI 1.9-2.9) were more likely to occur among patients on NVP. Patients receiving EFV were more likely to experience severe central nervous system events (OR 3.4, 95% CI 2.1-5.4). Similar associations were seen in children. Discussion: Compared to NVP, EFV is associated with a lower frequency of severe adverse events, in particular treatment discontinuations. This finding supports a move toward EFV-based therapy as the preferred first-line treatment regimen for HIV treatment within a public health approach. (C) 2013 Wolters Kluwer Health vertical bar Lippincott Williams & WilkinsKeywords
This publication has 41 references indexed in Scilit:
- A Review of the Virological Efficacy of the 4 World Health Organization–Recommended Tenofovir-Containing Regimens for Initial HIV TherapyClinical Infectious Diseases, 2012
- Efficacy and Safety of Once-Daily Nevirapine- or Efavirenz-Based Antiretroviral Therapy in HIV-Associated Tuberculosis: A Randomized Clinical TrialClinical Infectious Diseases, 2011
- Meta-analyses of Adverse Effects Data Derived from Randomised Controlled Trials as Compared to Observational Studies: Methodological OverviewPLoS Medicine, 2011
- Adverse Events in a Cohort of HIV Infected Pregnant and Non-Pregnant Women Treated with Nevirapine versus Non-Nevirapine Antiretroviral MedicationPLOS ONE, 2010
- Treatment Modification in Human Immunodeficiency Virus–Infected Individuals Starting Combination Antiretroviral Therapy Between 2005 and 2008JAMA Internal Medicine, 2010
- Search strategies to identify information on adverse effects: a systematic reviewJournal of the Medical Library Association, 2009
- GRADE: an emerging consensus on rating quality of evidence and strength of recommendationsBMJ, 2008
- Measuring inconsistency in meta-analysesBMJ, 2003
- Review papers : The statistical basis of meta-analysisStatistical Methods in Medical Research, 1993